Your browser is no longer supported. Please, upgrade your browser.
BHVN Biohaven Pharmaceutical Holding Company Ltd. daily Stock Chart
Biohaven Pharmaceutical Holding Company Ltd.
Index- P/E- EPS (ttm)-12.62 Insider Own4.30% Shs Outstand56.41M Perf Week10.17%
Market Cap3.48B Forward P/E- EPS next Y-6.88 Insider Trans-18.10% Shs Float48.09M Perf Month36.56%
Income-639.40M PEG- EPS next Q-2.50 Inst Own97.21% Short Float21.98% Perf Quarter38.14%
Sales1.20M P/S2902.98 EPS this Y-77.40% Inst Trans18.71% Short Ratio11.26 Perf Half Y11.57%
Book/sh2.16 P/B29.78 EPS next Y30.60% ROA-141.60% Target Price63.00 Perf Year13.92%
Cash/sh7.91 P/C8.14 EPS next 5Y- ROE-608.60% 52W Range26.56 - 67.86 Perf YTD18.15%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-5.22% Beta-
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin63.20% 52W Low142.17% ATR3.63
Employees647 Current Ratio3.90 Sales Q/Q- Oper. Margin- RSI (14)76.14 Volatility7.64% 6.77%
OptionableYes Debt/Eq2.36 EPS Q/Q-117.70% Profit Margin- Rel Volume1.05 Prev Close62.47
ShortableYes LT Debt/Eq2.36 Earnings- Payout- Avg Volume938.64K Price64.32
Recom1.80 SMA2025.70% SMA5051.31% SMA20039.60% Volume990,306 Change2.96%
Apr-17-20Initiated Cowen Outperform $45
Feb-10-20Downgrade Oppenheimer Outperform → Perform
Feb-06-20Initiated Mizuho Buy
Nov-22-19Initiated Wedbush Outperform
Jun-25-19Reiterated Canaccord Genuity Buy $89 → $84
May-06-19Initiated Goldman Buy $92
Apr-09-19Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-04-19Reiterated Needham Buy $48 → $56
Jul-03-18Reiterated Needham Buy $36 → $48
Jul-02-18Reiterated Needham Buy $36 → $48
Apr-05-18Downgrade Barclays Overweight → Equal Weight $30 → $25
Feb-22-18Reiterated Canaccord Genuity Buy $30 → $39
Dec-15-17Initiated Canaccord Genuity Buy $30
Oct-03-17Reiterated Needham Buy $43 → $36
Jun-01-20 04:05PM  
May-28-20 06:46AM  
May-21-20 07:30AM  
May-18-20 07:30AM  
May-15-20 07:33AM  
May-07-20 04:10PM  
May-04-20 08:47AM  
Apr-27-20 07:30AM  
Apr-16-20 05:42PM  
Apr-09-20 10:01AM  
Apr-07-20 07:48AM  
Mar-31-20 07:33AM  
Mar-30-20 07:30AM  
Mar-29-20 08:21PM  
Mar-23-20 07:30AM  
Mar-18-20 07:30AM  
Mar-13-20 07:30AM  
Mar-12-20 04:30PM  
Mar-04-20 09:55AM  
Feb-28-20 07:28AM  
Feb-27-20 04:11PM  
Feb-25-20 04:45PM  
Feb-14-20 07:33AM  
Feb-11-20 11:27AM  
Feb-10-20 04:17PM  
Feb-06-20 07:33AM  
Feb-04-20 10:22AM  
Jan-31-20 05:00PM  
Jan-30-20 09:02AM  
Jan-29-20 07:34AM  
Jan-28-20 05:13PM  
Jan-23-20 07:24AM  
Jan-19-20 10:23AM  
Jan-16-20 01:45PM  
Dec-26-19 11:45AM  
Dec-18-19 07:33AM  
Dec-17-19 07:30AM  
Dec-15-19 07:41AM  
Dec-06-19 04:32PM  
Dec-05-19 05:43PM  
Dec-04-19 08:31PM  
Dec-02-19 07:33AM  
Nov-13-19 01:00PM  
Nov-06-19 09:02AM  
Nov-05-19 07:30AM  
Nov-04-19 06:43PM  
Nov-01-19 04:15PM  
Oct-28-19 07:30AM  
Oct-26-19 09:35PM  
Sep-18-19 07:30AM  
Sep-10-19 07:30AM  
Sep-09-19 07:30AM  
Aug-08-19 05:02PM  
Aug-07-19 07:30AM  
Jul-31-19 07:30AM  
Jul-24-19 04:30AM  
Jul-22-19 07:30AM  
Jul-19-19 06:59PM  
Jul-15-19 10:22AM  
Jul-11-19 07:30AM  
Jul-10-19 05:00PM  
Jul-05-19 02:05PM  
Jul-02-19 12:15PM  
Jul-01-19 07:30AM  
Jun-26-19 11:15PM  
Jun-24-19 07:30AM  
Jun-18-19 10:07PM  
Jun-17-19 06:00PM  
Jun-14-19 12:03PM  
Jun-11-19 01:50PM  
May-07-19 11:30PM  
May-03-19 07:30AM  
May-02-19 01:21PM  
Apr-26-19 06:10AM  
Apr-16-19 08:10AM  
Apr-15-19 08:43AM  
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHILDS JOHN WDirectorApr 07Sale31.91200,0006,381,0322,476,938Apr 08 09:42 PM
CHILDS JOHN WDirectorApr 06Sale31.25150,0004,686,9372,676,938Apr 08 09:42 PM
AGUIAR ERICDirectorJan 22Option Exercise35.592,02171,9213,271Jan 24 06:43 PM
AGUIAR ERICDirectorJan 22Sale56.482,021114,1521,250Jan 24 06:43 PM
AGUIAR ERICDirectorJan 09Option Exercise9.2930,000278,70030,000Jan 10 07:46 PM
Gentile KimberlySVP, Clinical OperationsJan 09Option Exercise31.321,59049,8063,639Jan 10 07:46 PM
AGUIAR ERICDirectorJan 09Sale56.3930,0001,691,7000Jan 10 07:46 PM
Stock ElyseChief Medical OfficerJan 08Option Exercise55.9193752,388937Jan 10 07:46 PM
AGUIAR ERICDirectorJan 08Option Exercise55.911,25069,8881,250Jan 10 07:46 PM
Berman RobertSpecial Projects & Med OvrsghtDec 30Option Exercise0.61125,00076,250125,341Dec 31 07:33 PM
Berman RobertSpecial Projects & Med OvrsghtDec 30Sale53.22125,0006,652,052341Dec 31 07:33 PM
Stock ElyseChief Medical OfficerDec 18Option Exercise0.003,37503,375Dec 20 09:41 PM
Conway CharlesChief Scientific OfficerDec 18Option Exercise0.003,00007,000Dec 20 09:42 PM
Berman RobertSpecial Projects & Med OvrsghtDec 18Option Exercise0.006250625Dec 20 09:42 PM
Gentile KimberlySVP, Clinical OperationsDec 18Option Exercise0.003,75003,750Dec 20 09:40 PM
JONES WILLIAM A JRCCO-Migraine & Common DiseaseDec 18Option Exercise0.003,00003,000Dec 20 09:40 PM
Tilton JohnCCO-Rare & Neurologic DisorderDec 18Option Exercise0.001,25001,250Dec 20 09:41 PM
Coric VladChief Executive OfficerDec 18Option Exercise0.0010,950010,950Dec 20 09:39 PM
Engelhart JamesChief Financial OfficerDec 18Option Exercise0.003,70006,200Dec 20 09:39 PM
AGUIAR ERICDirectorDec 16Option Exercise20.793,53773,5343,537Dec 18 09:39 PM
AGUIAR ERICDirectorDec 16Sale55.133,537194,9850Dec 18 09:39 PM
AGUIAR ERICDirectorDec 09Option Exercise20.794,07284,6574,072Dec 11 09:43 PM
AGUIAR ERICDirectorDec 09Sale55.114,072224,4110Dec 11 09:43 PM
GREGORY JULIA PDirectorNov 22Option Exercise23.6312,000283,56012,000Nov 22 09:30 PM
AGUIAR ERICDirectorNov 22Option Exercise37.541,25046,9251,250Nov 22 09:37 PM
AGUIAR ERICDirectorNov 22Sale55.241,25069,0500Nov 22 09:37 PM
GREGORY JULIA PDirectorNov 22Sale54.7512,000656,9570Nov 22 09:30 PM
Gentile KimberlySVP, Clinical OperationsNov 21Option Exercise0.6121,06512,85021,065Nov 22 09:36 PM
Gentile KimberlySVP, Clinical OperationsNov 21Sale53.0421,0651,117,2050Nov 22 09:36 PM
Gentile KimberlySVP, Clinical OperationsNov 20Option Exercise0.613,9352,4003,935Nov 22 09:36 PM
AGUIAR ERICDirectorNov 20Option Exercise32.426,729218,1546,729Nov 22 09:37 PM
AGUIAR ERICDirectorNov 20Sale52.206,729351,2340Nov 22 09:37 PM
Gentile KimberlySVP, Clinical OperationsNov 20Sale53.033,935208,6650Nov 22 09:36 PM
Stock ElyseChief Medical OfficerOct 18Option Exercise10.8217,700191,51417,700Oct 25 08:39 PM
Stock ElyseChief Medical OfficerOct 18Sale45.0717,700797,7500Oct 25 08:39 PM
Stock ElyseChief Medical OfficerOct 15Option Exercise10.828008,656800Oct 17 06:29 PM
Stock ElyseChief Medical OfficerOct 15Sale45.0180036,0080Oct 17 06:29 PM
AGUIAR ERICDirectorSep 11Option Exercise25.5110,000255,10010,000Sep 13 04:34 PM
AGUIAR ERICDirectorSep 11Sale45.0010,000450,0000Sep 13 04:34 PM
Bailey GregoryDirectorAug 20Buy37.655,000188,2502,587,601Aug 21 04:11 PM
Engelhart JamesChief Financial OfficerJun 27Buy43.052,500107,6252,500Jun 28 07:11 AM
Berman RobertChief Medical OfficerJun 27Buy42.302,500105,750240,500Jun 28 07:09 AM
Coric VladChief Executive OfficerJun 26Buy40.225,000201,10019,130Jun 26 09:28 PM
CHILDS JOHN WDirectorJun 26Buy40.3710,000403,70010,000Jun 26 08:40 PM